Drug Development in Collaboration
Where alignment influences time, cost and risk
The most obvious focus in drug development is generating scientific data, but serious delays and costly rework often occur when strategic decisions are made too late or when sufficient alignment across functions and partners is lacking.
At Drug Development in Collaboration Ofichem and Uppsala Business Park invite three industry leaders from companies advancing drug programmes. They will share practical insights into how cross-functional dialogue influences real development decisions covering the entire scope from preclinical strategy to commercialisation.
The discussion will explore:
- Where collaboration directly impacts time-to-market
- How early alignment helps prevent costly downstream corrections
- Common decision bottlenecks throughout drug development
Join us for a focussed industry dialogue with peers navigating similar development challenges.
Register now
